Financings in Brief: UroMed
This article was originally published in The Gray Sheet
Executive Summary
UroMed: Files registration statement with the Securities and Exchange Commission for a secondary offering of 2.5 mil. shares, all of which are being offered by the company. On Oct. 18, the day the plans were announced, the issue closed at $10 a share. PaineWebber and Vector Securities International are managing the offering. Multi-center interim study results of the firm's first product, the Reliance female urinary incontinence device ("The Gray Sheet" Sept. 11, p. 10), were presented Oct. 12 at the American Urogynecologic Society annual scientific meeting ("The Gray Sheet" Oct. 16, In Brief). In its third quarter (ended Sept. 30), UroMed recorded its first-ever revenues of $404,662, which included sales of the Reliance device in Germany. UroMed booked a loss of $2.3 mil. for the period...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.